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Background: Among men in the U.S., prostate cancer is the most common cancer and the second leading
cause of cancer death. Despite its prevalence, there are few established risk factors for prostate cancer. Some
studies have found that intake of certain foods/nutrients may be associated with prostate cancer risk, but few have
accounted for how intake and metabolic factors may interact to influence bioavailable nutrient levels and subsequent
disease risk.
Presentation of the hypothesis: The composition of the gastrointestinal (GI) microbiome may influence metabolism
of dietary compounds and nutrients (e.g., plant phenols, calcium, choline) that may be relevant to prostate cancer risk.
We, therefore, propose the hypothesis that GI microbiota may have a markedly different composition among
individuals with higher prostate cancer risk. These individuals could have microbial profiles that are conducive to
intestinal inflammation and/or are less favorable for the metabolism and uptake of chemopreventive agents.
Testing the hypothesis: Because very little preliminary data exist on this potential association, a case–control study
may provide valuable information on this topic. Such a study could evaluate whether the GI microbial profile is
markedly different between three groups of individuals: healthy men, those with latent prostate cancer, and those with
invasive prostate cancer. Any findings could then be validated in a larger study, designed to collect a series of
specimens over time.
Implications of the hypothesis: Given the plethora of information emerging from the Human Microbiome Project,
this is an opportune time to explore associations between the microbiome and complex human diseases. Identification
of profiles that alter the host’s risk for disease may clarify inconsistencies in the literature on dietary factors and cancer
risk, and could provide valuable targets for novel cancer prevention strategies.
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Prostate cancer is the most common cancer among men
in the U.S. [1]. In 2012, approximately 241,740 new
diagnoses and 28,170 prostate cancer-related deaths
were expected in the U.S. alone (global incidence of
27.9 cases per 100,000) [1,2]. Lifetime risk for prostate
cancer is estimated to be 16%, and the median age at
diagnosis is 67 years [1].* Correspondence: scheurer@bcm.edu
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reproduction in any medium, provided the orDespite its prevalence, there are few established risk
factors for prostate cancer [3]. According to twin stud-
ies, a proportion of cases (10-40%) may be explained by
genetic factors [3-5]. However, dietary and lifestyle fac-
tors may also influence prostate cancer susceptibility
[3,6]. Intake of red meat [7-10], dairy products [11,12],
eggs [9,13,14], green tea [15,16], calcium [17-20], lyco-
pene [21-23], selenium [6,24], and fish oil [4,25] have all
been examined in relation to prostate cancer risk with
relatively inconsistent results. The inconsistency of these
findings may partly be due to the use of food intake mea-
sures as surrogates for bioavailable micronutrient levels,
resulting in some misclassification of nutrient/metabolite
exposures [26,27]. Differing levels of nutrient metabolisml Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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could bias the results of intake studies. Bioavailable micro-
nutrient levels are often determined by complex interac-
tions between intake and metabolism, which are generally
not accounted for in such studies.
While many studies have examined self-reported dietary
intake of certain foods or biomarkers of specific nutrient
levels, few studies have focused on the interactions be-
tween how intake and metabolic factors may be working
together to influence bioavailable nutrient levels and,
potentially, disease risk. The studies that have examined
interactions have mostly investigated how genetic vari-
ation may affect metabolism or intake (i.e., [28-30]). For
example, one recent study investigated the effect of a
single-nucleotide polymorphism (rs4988235) in the lac-
tase (LCT) gene on dairy intake, blood analytes, and
prostate cancer risk [29]. Although they did not find a
significant association with prostate cancer susceptibil-
ity, they did report that this variant was correlated with
milk intake, with the genotype that confers lower
tolerance of lactose-containing foods being associated
with lower dairy intake. Another study found that
obesity (and its inflammatory sequelae) may modify
the impact of arachidonic acid metabolism gene poly-
morphisms on prostate cancer risk [30]. Nevertheless,
genetic factors are only one component of what
determines the ability to absorb, convert, and retain
dietary nutrients [31-33].
Bioavailable micronutrient levels are not only dependent
upon metabolism-related genetic profiles, but are also
partly determined by the composition of one’s gastrointes-
tinal (GI) microbiota and the metabolic profiles of these
GI microorganisms [31,32,34-37]. In fact, the relationship
between the GI microbiome and dietary factors is
bidirectional– diet influences the composition of the
GI microbiome and the GI microbiome affects the
digestion and metabolism of dietary factors [37]. Inter-
actions between intake and many species of microbes
in the host GI tract have already been well documented
[31,32,38,39], and there are several excellent compre-
hensive review articles currently available on this topicTable 1 Examples of known associations between component
compounds*








Diadzein Soy phytoestrogen Unknown
Methylmercuric chloride Mercuric toxicity Unknown
*Examples identified through PharmacoMicrobiomics: The Drug-Microbiome Portal[36,37,39]. Here, we will highlight a few examples of
such interactions to show that the GI microbiome and
its related metabolic properties can potentially be highly
relevant to prostate cancer risk.
Microbial metabolism in the gut can affect dairy
product digestion [40], influence the composition of
bioactive fatty acids in host adipose tissue [35,41], alter
dietary phytochemical digestion/uptake [33], and con-
tribute to the generation of carcinogenic metabolites
and inflammation [33,42-45], among many other effects.
For example, Lactobacillus acidophilus, is commonly used
for probiotic supplementation, as it may aid in lactose
digestion [46,47], and Lactobacillus salivarius can help kill
Listeria, possibly preventing food-borne illness. Another
example involves phenolic compounds from tea, coffee,
and other plant-based dietary sources [33]. Some species
of GI microbes help digest phenols into biologically active
metabolites, which are more readily absorbed by the host
[33,48,49]. Resveratrol is one such phenol that has been
shown to have anti-inflammatory effects by altering eicos-
anoid production and inhibiting cytokines such as PTGS2,
IL6, and TNF [33,50]. By providing additional enzymatic
action, these and other GI microorganism can have major
impacts on the host’s digestive process. Some enzymes,
such as β-glucuronidases, that may be of particular rele-
vance to prostate cancer development are involved in con-
jugation and de-conjugation of sex hormones, such as
estrogen [51-53]. In fact, fecal microbial richness and
alpha diversity have previously been associated with total
urinary estrogen levels [52]. In addition to these examples,
a few other illustrations of potentially relevant relation-
ships between xenobiotics and GI microorganisms are
provided in Table 1.
A recent review article provided further rationale be-
hind why the GI bacterial community should be viewed
as a biodynamic system that interacts with its living
environment [38] and may, thus, affect disease risk.
This recent article focused on the hypothesis that GI
microbes could influence prostate cancer risk based on
the presence of isoflavone-metabolizing, equol-producing
bacteria. Equol, which has anti-androgenic properties, iss of the gastrointestinal microbiome and xenobiotic
Bacteria Effect Reference
Partial sequestration, limiting availability
to host
[54]




Metabolized into equol or non-estrogenic
metabolites
[57]
Reduction of mercuric tissue content [58]
(http://pharmacomicrobiomics.com/).
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idea of Slackia sp. NATTS strain bacteria metabolizing
daidzein into equol, which may, subsequently, influence
prostate cancer susceptibility, provides yet another ex-
ample of how the GI microbiome could impact digestion
and potentially have downstream systemic effects. With a
ratio of about 10 microbes for each eukaryotic cell in the
human body [59,60], it is likely that the human micro-
biome has major physiological and metabolic impacts that
we have yet to uncover.
Plotter and Blaser have suggested that human cancers
should be considered in the milieu of host-microbiome
interactions. They previously described three paradigms
relating how the microbiome may be involved in cancer
development and pathogenesis. The first involves constitu-
ents of the microbiome having inflammatory effects in a
lumenal organ. The second paradigm revolves around the
metabolic effects of the host’s GI microbiome indirectly
contributing to distal malignancies via the human estrobo-
lome. The estrobolome is defined as the set of enteric bac-
terial genes which code for proteins involved in estrogen
metabolism. This paradigm may be particularly relevant to
our proposed hypothesis due to the reported associations
between estrogens and prostate cancer risk [53,61]. The
third paradigm is related to the alteration of clinical
latency preceding malignancies.
Additionally, there are several specific mechanisms
(some of which could fall under one or more of the afore-
mentioned paradigms) through which the GI microbiome
could have downstream effects on cancer risk, including
competitive inhibition of pathogenic bacteria, production
of antibacterial compounds (i.e., bacteriocins) and acids,
gene transference between food-borne microbes and
members of the GI microbiota, and modulation of the
host’s immune system [37,62]. The exact mechanisms
by which the GI microbiome may distally affect cancer
risk is likely to be different depending on the cancer
site. Nevertheless, the first step to determining how in-
fluential the GI microbiome may be in prostate cancer
development is to assess whether there are key distinc-
tions in the microbial profiles of men who do and do
not develop aggressive disease.
Presentation of the hypothesis
Our hypothesis is that gastrointestinal microbiota may
have a markedly different composition among individ-
uals with higher prostate cancer risk. It is expected that
men who are more susceptible to the development of
aggressive disease will have similarities in their microbial/
metabolic profiles that diverge from the profiles of healthy
men. With regard to the microbial profiles of interest, our
hypothesis is not, per se, contingent upon the taxonomic
composition of the GI microbiome of low- versus high-
risk individuals, but rather the different metabolic andfunctional profiles represented by the GI microbial com-
munity. Given that different taxa of bacteria can have
similar metabolic effects, both taxonomic and metabolic
profiles should be identified and compared between high-
and low-risk men. Furthermore, because of the varied
effects that intestinal bacteria can have on the host, many
of which are still being uncovered, functional studies and
research into the specific mechanisms of action will be ne-
cessary to explain any microbial or metabolic differences
found. Individuals with higher prostate cancer susceptibil-
ity may potentially have microbial profiles that are more
conducive to intestinal inflammation and/or less favorable
for the metabolism and uptake of chemopreventive agents,
certain micronutrients, etc.
Testing the hypothesis
Testing our hypothesis may involve a distinct set of chal-
lenges. Although a case–control design seems appropriate,
a prospective study would better distinguish between
cancer-induced changes in the microbiome, as opposed to
changes that may play an etiologic or augmentative role in
carcinogenesis (Table 2). Khan et al. posit that there are at
least five mechanisms through which the microbiome
could be altered by cancer development [63]. Changes to
cell surface receptors and ligands may prevent a microbe
from selectively binding to certain host cells. The process
of carcinogenesis may also involve immunological alter-
ations, which can prevent recognition of pathogenic ver-
sus symbiotic bacteria. Further hormonal, anatomical, and
enzymatic changes that occur in the host’s body during
cancer development may produce a host environment that
inhibits survival of one microbe over another. Additional
concerns involve changes that may occur in the GI micro-
bial profile due to post-diagnostic alterations in diet
among cases during therapy.
Another concern regarding the temporality of poten-
tial associations between the microbiome and cancer de-
velopment relates to the “driver-passenger model” that
has been proposed for colorectal cancer [64]. Tjalsma
et al. posit that colorectal carcinogenesis may be spurred
by “driver” bacteria, which can initially induce DNA
damage, and are later replaced by “passenger” bacteria
that could either delay or enhance tumorogeneis. They
suggest that the changing microenvironment surround-
ing the growth of the tumor may alter selective pressures
and, thus, result in the driver bacteria being outcom-
peted by passenger bacteria (which are defined as com-
mensal organisms that may have tumor promoting or
suppressing properties). This driver-passenger model of
the involvement of the GI microbiome in colorectal
cancer development is probably less applicable to cancers
in tissues that have little direct exposure to the micro-
biome, such as the prostate. Nonetheless, it is possible that
physiological changes that occur after the development of
Table 2 Strengths and limitations of epidemiologic study designs for examining the associations between the
gastrointestinal microbiome and prostate cancer risk
Study design Strengths Limitations
Case–control: ● Quick ● Cannot truly establish temporality or
differentiate between cancer-induced and
pre-cancerous changes in the GI microbiomeDiagnostically-confirmed latent and invasive
prostate cancer cases compared to each other
and to matched controls
● Relatively inexpensive
● No follow-up required ● Difficult to obtain appropriate control group
Prospective Cohort: ● Ability to assess changes from multiple samples as
individuals transition from healthy to cancerous state
● Need very large sample size to be able to
obtain enough incident prostate cancer
casesLarge cohort of older men followed over time
with regular assessments of GI microbiome
and prostate cancer status ● Need long follow up time
● Can obtain data on incident cases ● Extremely expensive
● Potential biases due to loss to follow● Can continue to obtain data throughout course of
treatment and progression to assess post-diagnostic
longitudinal and treatment-related changes
● Can evaluate mortality as an end point
Retrospective Cohort: ● Likely to have clearer temporality between
assessment of microbial/metabolic profile and
prostate cancer development than in a case–control
study
● Requires availability of previously collected
and appropriately preserved samples
(or data)Previously collected samples on a large cohort
of men, who were healthy at baseline,
assessed for current prostate cancer status ● Participants must have been cancer-free at
time of sample collection
● Less expensive than prospective cohort study ● Multiple longitudinal samples are unlikely
to be available
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the composition of the GI microbiome. As a result, it is
important that the issue of temporality be considered in
any study of the possible associations between the GI
microbiome and prostate cancer risk.
While knowledge of microbial changes that occur due to
cancer development may be useful as potential diagnostic
or screening tools, identification of changes in gastrointes-
tinal microbiota that increase one’s risk for invasive cancer
would provide a key opportunity for cancer prevention. A
prospective study design, through expensive and time-
consuming, may afford opportunities to study both these
topics, if a large enough cohort of men could be recruited
and followed. Exploring the composition of the GI micro-
biome in relation to prostate cancer risk over time may
clarify the findings of previous studies that have inconsist-
ently reported associations between intake of various
foods/nutrients and prostate cancer susceptibility by better
encompassing the complex set of interactions involved in
digestion/metabolism. However, a longitudinal study may
present several obstacles related to feasibility, given the in-
cidence of prostate cancer among the general population,
the cost of repeated evaluations of microbial profiles, and
the need to successfully follow the participants over time
while minimizing loss to follow up.
Sample collection could pose another challenge for a
longitudinal study on this topic. Many protocols require
that stool samples be kept on ice and returned to the lab
within 24 hours of collection. A prospective study that
requires participants to collect stool, pack it, and returnit to the lab within one day may have high loss to follow
up, which could be differential between those who go on
to develop prostate cancer versus those who do not. This
type of selection bias would impact the study findings.
Thus, procedures should be streamlined, detailed instruc-
tions must be given to participants, and appropriate study
incentives should be provided. Ideally, sample collection
and processing should follow the protocols set forth and
established by The Human Microbiome Project [65,66].
Given the feasibility-related issues that may be associ-
ated with a longitudinal study on the GI microbiome and
prostate cancer susceptibility, initial studies may realistic-
ally need to be retrospective to determine whether this
topic is a fruitful area of research. Because little prelimin-
ary data exist on this potential association, a case–control
study (recruiting incident cases) may provide valuable
information, despite its limitations. The GI microbial
profiles of healthy men can be compared to those with
latent prostate cancer and those with invasive prostate
cancer. Alternatively, in a prospective cohort including
only diagnostically-confirmed cases, the GI microbiome
can feasibly be examined in relation to prostate cancer
survival over time among men with aggressive disease
to assess its prognostic value.
Implications of the hypothesis
Investigating the role of the human microbiome in the
etiology of complex multifactorial conditions, like cancer,
is still a relatively new field. Much research to date has
focused on profiling the composition of the microbiome
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with disease. The recent literature contains several profiles
of the bacterial diversity across the human digestive
tract [67-70]. However, inter-individual differences in
GI microbiome composition are a source of genetic/
metabolic variation that warrant thorough analysis as
potential predictors of disease susceptibility.
Even if the hypothesis proposed here is consistently
supported by our and other similar studies, establishing
causation for this association will likely be relatively dif-
ficult. Any differences in the GI microbiome detected
between low- and high-risk (or healthy and diseased)
men are likely to be neither sufficient nor necessary for
the development of malignancy. Furthermore, the asso-
ciation of interest is essentially a network of interactions
between the GI microbiome, dietary factors, and the
host’s other environmental and genetic susceptibility
factors. Studying such interactive relationships between
interconnected exogenous and endogenous factors has
always been challenging, but as the revolutionary new
field of molecular pathologic epidemiology continues to
evolve, the pathogenic processes behind complex diseases
can slowly be uncovered [71,72].
Molecular pathologic epidemiology can be described as
the study of the interactive relationships between lifestyle/
dietary factors and molecular tumoral characteristics on
the development or progression of a specific molecular
subtype of cancer [72]. Because this field will attempt to
examine more homogeneous and specific outcomes, while
also accounting for the network of biological interactions
inevitably at play in the disease process, etiologic relation-
ships that have long eluded us because of the heterogen-
eity of the case definition (or because of the reductionist
approach of simply examining main effects) may begin to
be revealed. It follows that simple standards, such as
Koch’s postulates or Hill’s criteria, which have previously
been used for establishing causality, are unlikely to be en-
tirely applicable to studies such as the one proposed here
(which will be focused on the multiple networks of inter-
actions constituted by the potential relationships between
the GI microbiome and prostate cancer) [73]. Therefore,
as the field of molecular pathologic epidemiology grows,
the criteria by which we assess causality must also evolve
to incorporate a more systemic approach.
Nevertheless, given the available information from the
Human Microbiome Project [74,75], this is an opportune
time to clarify associations between the microbiome and
complex diseases [66]. Identification of profiles that alter
the host’s disease risk may clarify inconsistencies in the
literature on dietary factors and cancer risk, and will likely
provide novel targets for cancer prevention strategies and
personalized medicine [33]. Such strategies may involve
personalized probiotic and vitamin/mineral supplementa-
tion, fecal transplant [76-78], or the use of antibiotics toachieve a more favorable microbial profile among men
whose GI microbiota may support a predisposition to
invasive prostate cancer.
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